[{"data":1,"prerenderedAt":23},["ShallowReactive",2],{"notifications-general-en":3,"compound-CBT-en":4},"Due to summer holidays, the laboratory will operate on a revised schedule from July 22 to August 9, 2026. Analysis results may take 7 to 10 days from sample receipt. Thank you for your understanding.",{"name":5,"shortname":6,"synonyms":7,"cas":8,"molMass":9,"pubchemLink":10,"structure":11,"important":12,"synthetic":13,"compoundClass":14,"asociationImage":17,"summarySet":18,"compoundEffectSet":22},"Cannabicitran","CBT","CBTC, (6aα,9β,10aα)-6a,7,8,9,10,10a-hexahydro-6,6,9-trimethyl-3-pentyl-1,9-epoxy-6H-dibenzo[b,d]pyran","31508-71-1",314.5,"https:\u002F\u002Fpubchem.ncbi.nlm.nih.gov\u002Fcompound\u002FCannabicitran","science\u002Fstructures\u002FCBT.png",true,false,{"id":15,"description":16},"2","Cannabinoids","",[19],{"summaryText":20,"language":21},"\u003Cp>Cannabicitran (CBT) is naturally found in hemp, albeit in rare quantities. It has demonstrated the ability to reduce intraocular pressure in rabbit tests, suggesting it may have potential use in managing conditions like glaucoma.The reduction in intraocular pressure is believed to be due to Cannabicitran's agonist activity at the NAGly receptor (GPR18), a target for many structurally related cannabinoids. \u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>",null,[],1785925832185]